Loading
Sleeping cancer cells survive by recycling their own contents. An old malaria drug blocks that recycling and is being tested in people with no visible cancer but detectable residual cells.
Dormant disseminated cells depend on autophagy for survival, and hydroxychloroquine plus mTOR inhibition has been tested in bone-marrow-positive breast cancer survivors in the CLEVER-type design at Johns Hopkins. The concept is attractive because it treats survivors while disease burden is at its minimum, but hydroxychloroquine is a weak, non-specific autophagy inhibitor; a potent selective ULK1 or ATG7 inhibitor would be the real test.
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
Shares Late recurrence, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Late recurrence, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Triple-negative breast cancer (TNBC).